Aberrant TGF-β signaling due to mutations or deletions in components of the TGF-β signaling pathway is observed, for instance, in colorectal cancer and pancreatic cancer [17,18,19,20]. This evidence concerns the gene TGFB1 and pancreatic neoplasm.